Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.41 |
| ▸ | PLG | P00747 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150195 | 0.80 | LOXL2 (0.56) | LOXL2HDAC3HDAC6NCOR2F10 | |
| SCHEMBL8174586 | 0.80 | RAB9A (0.38) | LOXL2ST14PRSS1PLGKDM4E | |
| SCHEMBL12025736 | 0.79 | LOXL2 (0.56) | LOXL2HDAC3HDAC6NCOR2F10 | |
| SCHEMBL752626 | 0.79 | TPMT (0.42) | PRSS1F2PRSS2PRSS3KMT2A | |
| SCHEMBL5395162 | 0.79 | LOXL2 (0.52) | LOXL2HDAC3HDAC6NCOR2F10 | |
| SCHEMBL326766 | 0.78 | ALDH1A1 (0.37) | KDM4ESMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL6789524 | 0.77 | LOXL2 (0.50) | LOXL2HDAC3HDAC6NCOR2F10 | |
| Hydrochloric Acid SCHEMBL6792710 | 0.77 | LOXL2 (0.50) | LOXL2HDAC3HDAC6NCOR2F10 | |
| SCHEMBL8363408 | 0.76 | LOXL2 (0.57) | LOXL2HDAC3HDAC6NCOR2F10 | |
| SCHEMBL15328960 | 0.76 | GAA (0.60) | F10ST14PRSS1PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611290-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2017-04-04 | — | — | US | disclosed |
| EP-2528895-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | MEDICINES CO LEIPZIG GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| US-8921319-B2 | Serine protease inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| EP-2590945-B1 | SERINE PROTEASE INHIBITORS | MEDICINES CO LEIPZIG GMBH (DE) | 2014-04-30 | — | — | EP | disclosed |
| US-20140073573-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8598206-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| US-20130267467-A1 | SERINE PROTEASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-10 | — | — | US | disclosed |
| EP-2590945-A2 | SERINE PROTEASE INHIBITORS | The Medicines Company (Leipzig) GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| EP-2528895-A2 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | The Medicines Company (Leipzig) GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| WO-2012004678-A2 | SERINE PROTEASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| US-20110301196-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| WO-2011094496-A2 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073573-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | SERPINE1, SPINT2, SERPINB1 | LOXL2 1527/4885HDAC3 1708/4885HDAC6 2789/4885 |
| US-20110301196-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | SERPINE1, SPINT2, SERPINB1 | LOXL2 1527/4885HDAC3 1708/4885HDAC6 2789/4885 |
| US-20130267467-A1 | SERINE PROTEASE INHIBITORS | SERPINE1, KLKB1, SERPINC1 | LOXL2 1016/4885HDAC3 2006/4885HDAC6 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.